Article thumbnail

The ABCB1 transporter gene and antidepressant response

By Eric J Peters, Victor Reus and Steven P Hamilton


P-glycoprotein, encoded by the ABCB1 gene, may modulate the brain concentration of several antidepressants. Functional genetic variation is thought to exist in this gene, and here we review several studies that have attempted to associate this variation with clinical response to antidepressant treatment

Topics: Review Article
Publisher: Biology Reports Ltd
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). An overview of the genetic dissection of complex traits. Adv Genet
  2. (1999). Audus KL: Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res
  3. (2007). Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls.
  4. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
  5. (2003). Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther
  6. (2008). Holsboer F: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron
  7. (2000). HolsboerF: Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a Pglycoprotein gene disruption. Neuropsychopharmacology
  8. (2003). JL: Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania.
  9. (2005). Leucht S: Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem
  10. (2007). MR: ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J
  11. (2003). MT: abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.
  12. (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.
  13. (2002). Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther
  14. (2003). PS: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA
  15. (2008). SP: Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE
  16. (2008). T: ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry
  17. (2000). U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA
  18. (2007). Watanabe J,InoueY,Someya T: Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit